Affordable Access

deepdyve-link
Publisher Website

Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.

Authors
  • Adamo, Margaret Peggy1
  • Boten, Jessica A1
  • Coyle, Linda M2
  • Cronin, Kathleen A1
  • Lam, Clara J K1
  • Negoita, Serban3
  • Penberthy, Lynne1
  • Stevens, Jennifer L2
  • Ward, Kevin C4
  • 1 Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
  • 2 Information Management Services Inc, Calverton, Maryland.
  • 3 Westat Inc, Rockville, Maryland.
  • 4 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. , (Georgia)
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Feb 15, 2017
Volume
123
Issue
4
Pages
697–703
Identifiers
DOI: 10.1002/cncr.30401
PMID: 27783399
Source
Medline
Keywords
License
Unknown

Abstract

The implied decimal error rate was only 1.93% of all cases in the current validation study, with a meaningful error rate of 5.81%. The reasons for the lower error rate in SEER are likely due to ongoing and rigorous quality control and visual editing processes by the central registries. The SEER program currently is reviewing and correcting PSA values back to 2004 and will re-release these data in the public use research file. Cancer 2017;123:697-703. © 2016 American Cancer Society.

Report this publication

Statistics

Seen <100 times